Your browser doesn't support javascript.
loading
A novel asymmetrical anti-HER2/CD3 bispecific antibody exhibits potent cytotoxicity for HER2-positive tumor cells.
Yu, Shengnan; Zhang, Jing; Yan, Yongxiang; Yao, Xudong; Fang, Lijuan; Xiong, Hui; Liu, Yang; Chu, Qian; Zhou, Pengfei; Wu, Kongming.
Afiliación
  • Yu S; Department of Oncology, Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology, 1095 Jiefang Avenue, Wuhan, 430030, People's Republic of China.
  • Zhang J; Wuhan YZY Biopharma Co., Ltd, Biolake, C2-1, No.666 Gaoxin Road, Wuhan, 430075, People's Republic of China.
  • Yan Y; Wuhan YZY Biopharma Co., Ltd, Biolake, C2-1, No.666 Gaoxin Road, Wuhan, 430075, People's Republic of China.
  • Yao X; Department of Orthopedics, Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, China.
  • Fang L; Wuhan YZY Biopharma Co., Ltd, Biolake, C2-1, No.666 Gaoxin Road, Wuhan, 430075, People's Republic of China.
  • Xiong H; Wuhan YZY Biopharma Co., Ltd, Biolake, C2-1, No.666 Gaoxin Road, Wuhan, 430075, People's Republic of China.
  • Liu Y; Wuhan YZY Biopharma Co., Ltd, Biolake, C2-1, No.666 Gaoxin Road, Wuhan, 430075, People's Republic of China.
  • Chu Q; Department of Oncology, Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology, 1095 Jiefang Avenue, Wuhan, 430030, People's Republic of China.
  • Zhou P; Wuhan YZY Biopharma Co., Ltd, Biolake, C2-1, No.666 Gaoxin Road, Wuhan, 430075, People's Republic of China. pfzhou@yzybio.com.
  • Wu K; Department of Oncology, Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology, 1095 Jiefang Avenue, Wuhan, 430030, People's Republic of China. kmwu@tjh.tjmu.edu.cn.
J Exp Clin Cancer Res ; 38(1): 355, 2019 Aug 14.
Article en En | MEDLINE | ID: mdl-31412896
Asunto(s)
Palabras clave
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Complejo CD3 / Anticuerpos Biespecíficos / Receptor ErbB-2 / Antineoplásicos Inmunológicos Tipo de estudio: Prognostic_studies Idioma: En Revista: J Exp Clin Cancer Res Año: 2019 Tipo del documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Complejo CD3 / Anticuerpos Biespecíficos / Receptor ErbB-2 / Antineoplásicos Inmunológicos Tipo de estudio: Prognostic_studies Idioma: En Revista: J Exp Clin Cancer Res Año: 2019 Tipo del documento: Article